Dysregulated expression of SKP2 and its role in hematological malignancies

References

• Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell. 1994;79:13–21.
   PubMed Web of Science ®Google Scholar
• Ovaa H, Kessler BM, Rolen U, et al. Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci USA. 2004;101:2253–2258.
   PubMed Web of Science ®Google Scholar
• Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours? Eur J Cancer. 2007;43:1125–1133.
   PubMed Web of Science ®Google Scholar
• Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–381.
   PubMed Web of Science ®Google Scholar
• Yang Y, Staudt LM. Protein ubiquitination in lymphoid malignancies. Immunol Rev. 2015;263:240–256.
   PubMed Web of Science ®Google Scholar
• Liu J, Shaik S, Dai X, et al. Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta. 2015;1855:50–60.
   PubMed Web of Science ®Google Scholar
• Kirkin V, Dikic I. Ubiquitin networks in cancer. Curr Opin Genet Dev. 2011;21:21–28.
   PubMed Web of Science ®Google Scholar
• Ande SR, Chen J, Maddika S. The ubiquitin pathway: an emerging drug target in cancer therapy. Eur J Pharmacol. 2009;625:199–205.
   PubMed Web of Science ®Google Scholar
• Lim MS, Adamson A, Lin Z, et al. Expression of Skp2, a p27(Kip1) ubiquitin ligase, in malignant lymphoma: correlation with p27(Kip1) and proliferation index. Blood. 2002;100:2950–2956.
   PubMed Web of Science ®Google Scholar
• Amati B, Vlach J. Kip1 meets SKP2: new links in cell-cycle control. Nat Cell Biol. 1999;1:E91–E93.
   PubMed Web of Science ®Google Scholar
• Carrano AC, Eytan E, Hershko A, et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol. 1999;1:193–199.
   PubMed Web of Science ®Google Scholar
• Uddin S, Bhat AA, Krishnankutty R, et al. Involvement of F-BOX proteins in progression and development of human malignancies. Semin Cancer Biol. 2016;36:18–32.
   PubMed Web of Science ®Google Scholar
• Lwin T, Hazlehurst LA, Dessureault S, et al. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood. 2007;110:1631–1638.
   PubMed Web of Science ®Google Scholar
• Xiang-Lan M, Zu-Lan S, Dan H, et al. Skp2/p27 expression profile is correlated with Epstein-Barr virus status in extranodal nasal-type natural killer cell lymphoma. Transl Res. 2008;151:303–308.
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain A, Ahmed M, et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008;216:483–494.
   PubMed Web of Science ®Google Scholar
• Old JB, Kratzat S, Hoellein A, et al. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis. Mol Cancer Res. 2010;8:353–362.
   PubMed Web of Science ®Google Scholar
• Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183:10–17.
   PubMed Web of Science ®Google Scholar
• Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol. 2003;13:41–47.
   PubMed Web of Science ®Google Scholar
• Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med. 1997;3:227–230.
   PubMed Web of Science ®Google Scholar
• Masciullo V, Ferrandina G, Pucci B, et al. p27Kip1 expression is associated with clinical outcome in advanced epithelial ovarian cancer: multivariate analysis. Clin Cancer Res. 2000;6:4816–4822.
   PubMed Web of Science ®Google Scholar
• Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941–945.
   PubMed Web of Science ®Google Scholar
• Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381–3385.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. Embo J. 2000;19:2069–2081.
   PubMed Web of Science ®Google Scholar
• Kossatz U, Dietrich N, Zender L, et al. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev. 2004;18:2602–2607.
   PubMed Web of Science ®Google Scholar
• Nakayama K, Nagahama H, Minamishima YA, et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell. 2004;6:661–672.
   PubMed Web of Science ®Google Scholar
• Cheng T, Rodrigues N, Dombkowski D, et al. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med. 2000;6:1235–1240.
   PubMed Web of Science ®Google Scholar
• Latres E, Chiarle R, Schulman BA, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA. 2001;98:2515–2520.
   PubMed Web of Science ®Google Scholar
• Hnit SS, Xie C, Yao M, et al. p27(Kip1) signaling: transcriptional and post-translational regulation. Int J Biochem Cell Biol. 2015;68:9–14.
   PubMed Web of Science ®Google Scholar
• Chan CH, Lee SW, Wang J, et al. Regulation of Skp2 expression and activity and its role in cancer progression. Scientific World Journal. 2010;10:1001–1015.
   Web of Science ®Google Scholar
• Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. 2008;8:438–449.
   PubMed Web of Science ®Google Scholar
• Schulman BA, Carrano AC, Jeffrey PD, et al. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature. 2000;408:381–386.
   PubMed Web of Science ®Google Scholar
• Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Semin Cell Dev Biol. 2005;16:323–333.
   PubMed Web of Science ®Google Scholar
• Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene. 2004;23:4225–4231.
   PubMed Web of Science ®Google Scholar
• Yang XJ. Lysine acetylation and the bromodomain: a new partnership for signaling. Bioessays. 2004;26:1076–1087.
   PubMed Web of Science ®Google Scholar
• Wang Z, Inuzuka H, Zhong J, et al. Identification of acetylation-dependent regulatory mechanisms that govern the oncogenic functions of Skp2. Oncotarget. 2012;3:1294–1300.
   PubMed Web of Science ®Google Scholar
• Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008;112:1415–1424.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Kotake Y, Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 2009;100:1374–1381.
   PubMed Web of Science ®Google Scholar
• Satija YK, Bhardwaj A, Das S. A portrayal of E3 ubiquitin ligases and deubiquitylases in cancer. Int J Cancer. 2013;133:2759–2768.
   PubMed Web of Science ®Google Scholar
• Wang G, Chan CH, Gao Y, et al. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer. 2012;31:169–177.
   PubMed Web of Science ®Google Scholar
• Yang C, Nan H, Ma J, et al. High Skp2/low p57(Kip2) expression is associated with poor prognosis in human breast carcinoma. Breast Cancer (Auckl). 2015;9:13–21.
   PubMed Web of Science ®Google Scholar
• Min YH, Cheong JW, Lee MH, et al. Elevated S-phase kinase-associated protein 2 protein expression in acute myelogenous leukemia: its association with constitutive phosphorylation of phosphatase and tensin homologue protein and poor prognosis. Clin Cancer Res. 2004;10:5123–5130.
   PubMed Web of Science ®Google Scholar
• Lee SW, Li CF, Jin G, et al. Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress. Mol Cell. 2015;57:1022–1033.
   PubMed Web of Science ®Google Scholar
• Xu SY, Wang F, Wei G, et al. S-phase kinase-associated protein 2 knockdown blocks colorectal cancer growth via regulation of both p27 and p16 expression. Cancer Gene Ther. 2013;20:690–694.
   PubMed Web of Science ®Google Scholar
• Lu W, Liu S, Li B, et al. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget. 2015;6:771–788.
   PubMed Web of Science ®Google Scholar
• Mamillapalli R, Gavrilova N, Mihaylova VT, et al. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr Biol. 2001;11:263–267.
   PubMed Web of Science ®Google Scholar
• Lin HK, Chen Z, Wang G, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010;464:374–379.
   PubMed Web of Science ®Google Scholar
• Ji P, Jiang H, Rekhtman K, et al. An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell. 2004;16:47–58.
   PubMed Web of Science ®Google Scholar
• Dehan E, Pagano M. Skp2, the FoxO1 hunter. Cancer Cell. 2005;7:209–210.
   PubMed Web of Science ®Google Scholar
• Andreu EJ, Lledo E, Poch E, et al. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res. 2005;65:3264–3272.
   PubMed Web of Science ®Google Scholar
• Lin HK, Wang G, Chen Z, et al. Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nat Cell Biol. 2009;11:420–432.
   PubMed Web of Science ®Google Scholar
• Uddin S, Ahmed M, Hussain AR, et al. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest. 2009;89:1115–1127.
   PubMed Web of Science ®Google Scholar
• Iskandarani A, Bhat AA, Siveen KS, et al. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells. J Transl Med. 2016;14:69.
   PubMed Web of Science ®Google Scholar
• Yokoi S, Yasui K, Mori M, et al. Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes. Am J Pathol. 2004;165:175–180.
   PubMed Web of Science ®Google Scholar
• Yokoi S, Yasui K, Saito-Ohara F, et al. A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol. 2002;161:207–216.
   PubMed Web of Science ®Google Scholar
• Sanada T, Yokoi S, Arii S, et al. Skp2 overexpression is a p27Kip1-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci. 2004;95:969–976.
   PubMed Web of Science ®Google Scholar
• Saigusa K, Hashimoto N, Tsuda H, et al. Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas. Cancer Sci. 2005;96:676–683.
   PubMed Web of Science ®Google Scholar
• Furuhata A, Kimura A, Shide K, et al. p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation. Biochem Biophys Res Commun. 2009;383:411–416.
   PubMed Web of Science ®Google Scholar
• Chen JY, Wang MC, Hung WC. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leuk Res. 2009;33:1520–1524.
   PubMed Web of Science ®Google Scholar
• Shanmugasundaram K, Block K, Nayak BK, et al. PI3K regulation of the SKP-2/p27 axis through mTORC2. Oncogene. 2013;32:2027–2036.
   PubMed Web of Science ®Google Scholar
• Inuzuka H, Gao D, Finley LW, et al. Acetylation-dependent regulation of Skp2 function. Cell. 2012;150:179–193.
   PubMed Web of Science ®Google Scholar
• Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle. 2004;3:779–788.
   PubMed Web of Science ®Google Scholar
• Drobnjak M, Melamed J, Taneja S, et al. Altered expression of p27 and Skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res. 2003;9:2613–2619.
   PubMed Web of Science ®Google Scholar
• Li Q, Murphy M, Ross J, et al. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol. 2004;31:633–642.
   PubMed Web of Science ®Google Scholar
• Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer. Oncogene. 2005;24:3448–3458.
   PubMed Web of Science ®Google Scholar
• Bornstein G, Ganoth D, Hershko A. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate. Proc Natl Acad Sci USA. 2006;103:11515–11520.
   PubMed Web of Science ®Google Scholar
• Min KW, Kwon MJ, Park HS, et al. CAND1 enhances deneddylation of CUL1 by COP9 signalosome. Biochem Biophys Res Commun. 2005;334:867–874.
   PubMed Web of Science ®Google Scholar
• Schmidt MW, McQuary PR, Wee S, et al. F-box-directed CRL complex assembly and regulation by the CSN and CAND1. Mol Cell. 2009;35:586–597.
   PubMed Web of Science ®Google Scholar
• Wu JT, Chan YR, Chien CT. Protection of cullin-RING E3 ligases by CSN-UBP12. Trends Cell Biol. 2006;16:362–369.
   PubMed Web of Science ®Google Scholar
• Nogueira V, Sundararajan D, Kwan JM, et al. Akt-dependent Skp2 mRNA translation is required for exiting contact inhibition, oncogenesis, and adipogenesis. EMBO J. 2012;31:1134–1146.
   PubMed Web of Science ®Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9:667–676.
   PubMed Web of Science ®Google Scholar
• Gao D, Inuzuka H, Tseng A, et al. Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009;11:397–408.
   PubMed Web of Science ®Google Scholar
• Matsuoka T, Yashiro M. The role of PI3K/Akt/mTOR signaling in gastric carcinoma. Cancer. 2014;6:1441–1463.
   Web of Science ®Google Scholar
• Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4:257–262.
   PubMed Web of Science ®Google Scholar
• Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood. 1996;88:645–656.
   PubMed Web of Science ®Google Scholar
• Klepfish A, Sarid R, Shtalrid M, et al. Primary effusion lymphoma (PEL) in HIV-negative patients-a distinct clinical entity. Leuk Lymphoma. 2001;41:439–443.
   PubMed Web of Science ®Google Scholar
• Baresova P, Pitha PM, Lubyova B. Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability. J Biol Chem. 2012;287:16199–16208.
   PubMed Web of Science ®Google Scholar
• Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA. 2000;97:3260–3265.
   PubMed Web of Science ®Google Scholar
• Hussain AR, Ahmed M, Ahmed SO, et al. Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion lymphoma cells. Leuk Lymphoma. 2009;50:1204–1213.
   PubMed Web of Science ®Google Scholar
• Hussain AR, Khan AS, Ahmed SO, et al. Apigenin induces apoptosis via downregulation of S-phase kinase-associated protein 2-mediated induction of p27Kip1 in primary effusion lymphoma cells. Cell Prolif. 2010;43:170–183.
   PubMed Web of Science ®Google Scholar
• Escalon MP, Lossos IS. Pharmacotherapy of large B-cell lymphoma. Expert Opin Pharmacother. 2008;9:2247–2258.
   PubMed Web of Science ®Google Scholar
• Fisher RI. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma. Cancer Chemother Pharmacol. 1997;40Suppl:S42–S46.
   Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3’-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006;108:4178–4186.
   PubMed Web of Science ®Google Scholar
• Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis. 2001;27:206–216.
   PubMed Web of Science ®Google Scholar
• Markovic O, Marisavljevic D, Cemerikic V, et al. Clinical and prognostic significance of apoptotic profile in patients with newly diagnosed nodal diffuse large B-cell lymphoma (DLBCL). Eur J Haematol. 2011;86:246–255.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Okamura T. [Prognostic significance of Skp2 and p27(kip) in diffuse large B cell lymphoma]. Rinsho Ketsueki. 2010;51:1741–1747.
   PubMedGoogle Scholar
• Seki R, Ohshima K, Fujisaki T, et al. Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol. 2010;21:833–841.
   PubMed Web of Science ®Google Scholar
• Abdou AG, Asaad NY, Abd El-Wahed MM, et al. The prognostic value of Skp2 expression in Egyptian diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol. 2012;20:47–55.
   PubMedGoogle Scholar
• Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016;5:1882.
   Google Scholar
• Sidiropoulos KG, Martinez-Escala ME, Yelamos O, et al. Primary cutaneous T-cell lymphomas: a review. J Clin Pathol. 2015;68:1003–1010.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Klemke CD, Brenner D, Weiss EM, et al. Lack of T-cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res. 2009;69:4175–4183.
   PubMed Web of Science ®Google Scholar
• Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol. 2007;7:532–542.
   PubMed Web of Science ®Google Scholar
• Peter ME, Hadji A, Murmann AE, et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015;22:549–559.
   PubMed Web of Science ®Google Scholar
• Curiel-Lewandrowski C, Yamasaki H, Si CP, et al. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma. J Clin Invest. 2011;121:4838–4849.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tuzova M, Xiao ZX, et al. Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. J Immunol. 2008;180:402–408.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Gianfelici V, O’Brien SM, et al. Advances in the genetics and therapy of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2016;35:e314–e322.
   PubMedGoogle Scholar
• Tosello V, Ferrando AA. The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol. 2013;4:199–210.
   PubMedGoogle Scholar
• Dohda T, Maljukova A, Liu L, et al. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp Cell Res. 2007;313:3141–3152.
   PubMed Web of Science ®Google Scholar
• Shet AS, Jahagirdar BN, Verfaillie CM. Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia. 2002;16:1402–1411.
   PubMed Web of Science ®Google Scholar
• Granatowicz A, Piatek CI, Moschiano E, et al. An overview and update of chronic myeloid leukemia for primary care physicians. Korean J Fam Med. 2015;36:197–202.
   PubMed Web of Science ®Google Scholar
• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172.
   PubMed Web of Science ®Google Scholar
• Chen JY, Wang MC, Hung WC. Bcr-Abl-induced tyrosine phosphorylation of Emi1 to stabilize Skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells. J Cell Physiol. 2011;226:407–413.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen Y, Saha MN, et al. Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia. 2015;29:715–726.
   PubMed Web of Science ®Google Scholar
• Techasen A, Loilome W, Namwat N, et al. Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. Cancer Sci. 2010;101:658–665.
   PubMed Web of Science ®Google Scholar
• Xu K, Belunis C, Chu W, et al. Protein-protein interactions involved in the recognition of p27 by E3 ubiquitin ligase. Biochem J. 2003;371:957–964.
   PubMed Web of Science ®Google Scholar
• Cardozo T, Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat Rev Mol Cell Biol. 2004;5:739–751.
   PubMed Web of Science ®Google Scholar
• Zhan F, Colla S, Wu X, et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109:4995–5001.
   PubMed Web of Science ®Google Scholar
• Rodriguez S, Wang L, Mumaw C, et al. The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs. Blood. 2011;117:6509–6519.
   PubMed Web of Science ®Google Scholar
• Wang J, Han F, Wu J, et al. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood. 2011;118:5429–5438.
   PubMed Web of Science ®Google Scholar
• Wang J, Han F, Lee SW, et al. E3-ligase Skp2 regulates β-catenin expression and maintains hematopoietic stem cell homing. Biochem Biophys Res Commun. 2014;445:566–571.
   PubMed Web of Science ®Google Scholar
• Chan CH, Morrow JK, Li CF, et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell. 2013;154:556–568.
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang F, Jiang L, et al. Inhibition of SKP2 sensitizes bromocriptine induced apoptosis in human prolactinoma cells. Cancer Res Treat. 2017;49:358–373.
   PubMedGoogle Scholar
• Chang CC, Chen WC, Ho TF, et al. Development of natural anti-tumor drugs by microorganisms. J Biosci Bioeng. 2011;111:501–511.
   PubMed Web of Science ®Google Scholar
• Perez-Tomas R, Vinas M. New insights on the antitumoral properties of prodiginines. CMC. 2010;17:2222–2231.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Huang D, Roberts A. Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol. 2014;51:219–227.
   PubMed Web of Science ®Google Scholar
• Hsieh HY, Shieh JJ, Chen CJ, et al. Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells. Br J Pharmacol. 2012;166:2095–2108.
   PubMed Web of Science ®Google Scholar
• Chen B, Liu Q, Popowich A, et al. Therapeutic and analytical applications of arsenic binding to proteins. Metallomics. 2015;7:39–55.
   PubMed Web of Science ®Google Scholar
• Shen S, Li XF, Cullen WR, et al. Arsenic binding to proteins. Chem Rev. 2013;113:7769–7792.
   PubMed Web of Science ®Google Scholar
• Gao JK, Wang LX, Long B, et al. Arsenic trioxide inhibits cell growth and invasion via down-regulation of Skp2 in pancreatic cancer cells. Asian Pac J Cancer Prev. 2015;16:3805–3810.
   PubMedGoogle Scholar
• Uddin S, Ahmed M, Bavi P, et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res. 2008;68:3379–3388.
   PubMed Web of Science ®Google Scholar
• Huang HC, Lin CL, Lin JK. 1,2,3,4,6-penta-O-galloyl-β-D-glucose, quercetin, curcumin and lycopene induce cell-cycle arrest in MDA-MB-231 and BT474 cells through downregulation of Skp2 protein. J Agric Food Chem. 2011;59:6765–6775.
   PubMed Web of Science ®Google Scholar
• Zhao S, Pu JX, Sun HD, et al. [Longikaurin A induces apoptosis of multiple myeloma H929 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20:611–615.
   PubMedGoogle Scholar
• Liao YJ, Bai HY, Li ZH, et al. Longikaurin A, a natural ent-kaurane, induces G2/M phase arrest via downregulation of Skp2 and apoptosis induction through ROS/JNK/c-Jun pathway in hepatocellular carcinoma cells. Cell Death Dis. 2014;5:e1137.
   PubMed Web of Science ®Google Scholar
• Roy S, Kaur M, Agarwal C, et al. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther. 2007;6:2696–2707.
   PubMed Web of Science ®Google Scholar
• Huang HC, Way TD, Lin CL, et al. EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein. Endocrinology. 2008;149:5972–5983.
   PubMed Web of Science ®Google Scholar
• Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4:46–56.
   PubMed Web of Science ®Google Scholar
• Shabahang M, Buras RR, Davoodi F, et al. Growth inhibition of HT-29 human colon cancer cells by analogues of 1,25-dihydroxyvitamin D3. Cancer Res. 1994;54:4057–4064.
   PubMed Web of Science ®Google Scholar
• Li P, Li C, Zhao X, et al. p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase. J Biol Chem. 2004;279:25260–25267.
   PubMed Web of Science ®Google Scholar
• Kim SH, Chen G, King AN, et al. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 2012;77:265–271.
   PubMed Web of Science ®Google Scholar
• Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem. 2003;278:46862–46868.
   PubMed Web of Science ®Google Scholar
• Dow R, Hendley J, Pirkmaier A, et al. Retinoic acid-mediated growth arrest requires ubiquitylation and degradation of the F-box protein Skp2. J Biol Chem. 2001;276:45945–45951.
   PubMed Web of Science ®Google Scholar
• Hsu JD, Kao SH, Ou TT, et al. Gallic acid induces G2/M phase arrest of breast cancer cell MCF-7 through stabilization of p27(Kip1) attributed to disruption of p27(Kip1)/Skp2 complex. J Agric Food Chem. 2011;59:1996–2003.
   PubMed Web of Science ®Google Scholar
• Wang Z, Fukushima H, Inuzuka H, et al. Skp2 is a promising therapeutic target in breast cancer. Front Oncol. 2012;1:57. doi: 10.3389/fonc.2011.00057
   Google Scholar